{"id":225679,"date":"2025-04-01T10:27:58","date_gmt":"2025-04-01T10:27:58","guid":{"rendered":"https:\/\/evertise.net\/?p=115150"},"modified":"2025-04-01T10:27:58","modified_gmt":"2025-04-01T10:27:58","slug":"generic-drugs-market-is-to-grow-at-a-5-22-cagr-is-reported-by-maximize-market-research","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2025\/04\/01\/generic-drugs-market-is-to-grow-at-a-5-22-cagr-is-reported-by-maximize-market-research\/","title":{"rendered":"Generic Drugs Market is to grow at a 5.22% CAGR, is reported by Maximize Market Research"},"content":{"rendered":"

<\/span><\/p>\n


\nGeneric Drugs Market is expected to reach USD 681.57 Bn by 2032. Increasing incidence of chronic diseases and cost-effective characteristics of these drugs are some of the factors which\u2002will help in the increase in the generic drugs market.<\/p>\n

Market <\/strong>to Hit\u2002USD 681.57 Bn by 2032<\/strong><\/p>\n

Generic Drugs Market<\/a> had a value of USD 453.65 Bn in 2024, and it is predicted to increase at a compound annual growth rate (CAGR) of 5.22%, and by 2032 reach USD 681.57 Bn. In 2024 the European Generic Drugs\u00a0Market \u2002was estimated to be worth USD 65.1 billion. Furthermore, the market is projected to attain a valuation of approximately USD 113.2 billion by 2033, with a compound annual growth rate (CAGR) of 6.3%\u2002during the period from 2025 to 2033. Chronic diseases account for\u2002a large part of the problem. As per WHO, cardiovascular diseases cause\u200232% of all global deaths while diabetes affects more than 537 million adults worldwide. The demand for cost-effective drugs to treat\u2002these diseases has resulted in an increasing demand for generic medicines. The U.S. government has introduced policies to facilitate generics use, and in 2023,\u2002the Food and Drug Administration approved more than 800 generic drugs. In Europe, there is also an increase in the use of generics, most evidently in Germany and the UK, which have\u2002the most stringent price control measures and push for generic substitution.<\/p>\n

Dive Deeper into Data: Get Your In-Depth Sample Now!<\/strong><\/p>\n

https:\/\/www.maximizemarketresearch.com\/request-sample\/25900\/<\/a> <\/strong><\/p>\n

Market Segmentation<\/strong><\/p>\n

By Product: Super Generics<\/strong>, market share of Generic Drugs\u00a0Market is 38% in 2024, on the basis of the growing use of these improved therapeutic benefits over simple generics. Super generics have new drug delivery systems and modified-release mechanisms\u2002unlike the traditional generics making them more suitable to patients who are suffering from chronic diseases as compared to the traditional generics. The super generics market is projected to increase as demand rises for extended-release and targeted drug delivery systems.<\/p>\n

By Application: Central Nervous System (CNS) Drugs<\/strong>, segment led the market owing to a higher incidence of neurological disorders like epilepsy, depression,\u2002and Alzheimer\u2019s disease in 2024. The increasing demand for CNS generic drugs could be attributed to their affordable nature as well\u2002as availability. The World Health Organization estimates that more than 280 million people around the world suffer from depression, and the incidence of Alzheimer\u2019s is expected to triple\u2002by 2050.<\/p>\n

Market Regional Analysis<\/strong><\/p>\n

North America,<\/strong> accounted for 33.21% of the Generic Drugs\u00a0Market in 2024, primarily due to the strong regulatory frameworks and\u2002high expenditure on health in the U.S. In\u20022023 alone, the U.S. FDA approved more than 800 generic drugs, which now represent almost 90% of all prescriptions filled in the United States. The Canadian market is\u2002also growing, with increasing government action to reduce branded drug prices.<\/p>\n

Europe, <\/strong>the region is dominated by France and the UK, and by Germany, due to its high penetration levels\u2002and its tendency to introduce price regulation policies. The European Medicines Agency (EMA) advocates for generic drug approval, which propels further market\u2002growth.<\/p>\n

Asia Pacific<\/strong>, with cost-effective and easier manufacturing, and government initiatives encouraging the use of generics, countries such as India and China are expected to account for a CAGR of\u20026.42% for the market. India is home to more than 3,000 pharmaceutical companies, and is the world\u2019s largest producer of generic drugs.<\/p>\n

Market Competitive Landscape<\/strong><\/p>\n

Teva Pharmaceuticals (Revenue: $15.9 Billion, 2024)- Teva introduced UZEDY, a long-acting injectable suspension for the\u2002therapy of schizophrenia in adults, in May 2023.<\/p>\n

Pfizer (Revenue: $81.3\u2002Billion, 2024) Pfizer is one of the companies that released biosimilar versions of Humira (adalimumab) in 2023.<\/p>\n

Sun Pharma (Revenue: $5.7 Billion; 2024) Specifics on Sun Pharma\u2019s expansions in dermatology and oncology generics in\u20022024 were not available through the sources analyzed.<\/p>\n

Mylan (Viatris) (Revenue: $12.1 Billion, 2024) Information on which European and\u2002which Asian manufacturers Mylan acquired during 2024 was not reported in the provided sources.<\/p>\n

Market Recent Trends and Developments<\/strong><\/p>\n